These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
71 related articles for article (PubMed ID: 15156435)
1. Use of pharmacodynamic end points in the evaluation of gatifloxacin for the treatment of acute maxillary sinusitis. Ambrose PG; Anon JB; Owen JS; Van Wart S; McPhee ME; Bhavnani SM; Piedmonte M; Jones RN Clin Infect Dis; 2004 Jun; 38(11):1513-20. PubMed ID: 15156435 [TBL] [Abstract][Full Text] [Related]
2. Oral garenoxacin in the treatment of acute bacterial maxillary sinusitis: a Phase II, multicenter, noncomparative, open-label study in adult patients undergoing sinus aspiration. Lopez Sisniega J; Profant M; Kostrica R; Waskin H Clin Ther; 2007 Aug; 29(8):1632-44. PubMed ID: 17919545 [TBL] [Abstract][Full Text] [Related]
3. Serial sinus aspirate samples during high-dose, short-course levofloxacin treatment of acute maxillary sinusitis. Anon JB; Paglia M; Xiang J; Ambrose PG; Jones RN; Kahn JB Diagn Microbiol Infect Dis; 2007 Jan; 57(1):105-7. PubMed ID: 17178300 [TBL] [Abstract][Full Text] [Related]
4. Use of pharmacodynamic endpoints for the evaluation of levofloxacin for the treatment of acute maxillary sinusitis. Ambrose PG; Anon JB; Bhavnani SM; Okusanya OO; Jones RN; Paglia MR; Kahn J; Drusano GL Diagn Microbiol Infect Dis; 2008 May; 61(1):13-20. PubMed ID: 18313879 [TBL] [Abstract][Full Text] [Related]
5. Bacteriological findings and antimicrobial susceptibility in chronic sinusitis with nasal polyp. Kim HJ; Lee K; Yoo JB; Song JW; Yoon JH Acta Otolaryngol; 2006 May; 126(5):489-97. PubMed ID: 16698698 [TBL] [Abstract][Full Text] [Related]
7. Gatifloxacin and the elderly: pharmacokinetic-pharmacodynamic rationale for a potential age-related dose reduction. Ambrose PG; Bhavnani SM; Cirincione BB; Piedmonte M; Grasela TH J Antimicrob Chemother; 2003 Sep; 52(3):435-40. PubMed ID: 12917247 [TBL] [Abstract][Full Text] [Related]
8. Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae. Noreddin AM; Hoban DJ; Zhanel GG Int J Antimicrob Agents; 2005 Aug; 26(2):120-5. PubMed ID: 16046101 [TBL] [Abstract][Full Text] [Related]
9. Eradication of pathogens from the nasopharynx after therapy of acute maxillary sinusitis with low- or high-dose amoxicillin/clavulanic acid. Brook I; Foote PA; Hausfeld JN Int J Antimicrob Agents; 2005 Nov; 26(5):416-9. PubMed ID: 16226017 [TBL] [Abstract][Full Text] [Related]
10. Sparfloxacin for the treatment of acute bacterial maxillary sinusitis documented by sinus puncture. Garrison N; Spector S; Buffington D; Stafford C; Granito K; Zhang H; Talbot GH Ann Allergy Asthma Immunol; 2000 Jan; 84(1):63-71. PubMed ID: 10674567 [TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic analysis of ceftriaxone, gatifloxacin,and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation. Frei CR; Burgess DS Pharmacotherapy; 2005 Sep; 25(9):1161-7. PubMed ID: 16164390 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic/pharmacodynamic modelling of the bactericidal activity of free lung concentrations of levofloxacin and gatifloxacin against Streptococcus pneumoniae. Tasso L; de Andrade C; Dalla Costa T Int J Antimicrob Agents; 2011 Oct; 38(4):307-13. PubMed ID: 21802907 [TBL] [Abstract][Full Text] [Related]
13. New fluoroquinolones in lower respiratory tract infections and emerging patterns of pneumococcal resistance. Ferrara AM Infection; 2005 Jun; 33(3):106-14. PubMed ID: 15940410 [TBL] [Abstract][Full Text] [Related]
14. Bacterial findings in acute maxillary sinusitis--European study. Penttilä M; Savolainen S; Kiukaanniemi H; Forsblom B; Jousimies-Somer H Acta Otolaryngol Suppl; 1997; 529():165-8. PubMed ID: 9288300 [TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Ambrose PG; Grasela DM; Grasela TH; Passarell J; Mayer HB; Pierce PF Antimicrob Agents Chemother; 2001 Oct; 45(10):2793-7. PubMed ID: 11557471 [TBL] [Abstract][Full Text] [Related]
17. Comparison of the efficacy and safety of moxifloxacin and trovafloxacin for the treatment of acute, bacterial maxillary sinusitis in adults. Klossek JM; Siegert R; Nikolaidis P; Arvis P; Leberre MA; J Laryngol Otol; 2003 Jan; 117(1):43-51. PubMed ID: 12590855 [TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections. Van Wart S; Phillips L; Ludwig EA; Russo R; Gajjar DA; Bello A; Ambrose PG; Costanzo C; Grasela TH; Echols R; Grasela DM Antimicrob Agents Chemother; 2004 Dec; 48(12):4766-77. PubMed ID: 15561855 [TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic assessment of gatifloxacin against Streptococcus pneumoniae. Mattoes HM; Banevicius M; Li D; Turley C; Xuan D; Nightingale CH; Nicolau DP Antimicrob Agents Chemother; 2001 Jul; 45(7):2092-7. PubMed ID: 11408228 [TBL] [Abstract][Full Text] [Related]
20. In vitro efficacy and pharmacodynamic indices for antibiotics against coagulase-negative staphylococcus endophthalmitis isolates. Harper T; Miller D; Flynn HW Ophthalmology; 2007 May; 114(5):871-5. PubMed ID: 17383732 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]